ClinPro Expands Business Development and Medical Affairs Teams
ClinPro, Inc., a full-service clinical research organization (CRO), today announced the expansion of its business development and medical affairs divisions with the appointment of Jeffrey Yablon as director, business development, Matthew Stannard as senior manager of business development and Linda Brown as senior project manager.
BOUND BROOK, NJ (May 12, 2005) -- ClinPro, Inc., a full-service clinical research organization (CRO), today announced the expansion of its business development and medical affairs divisions with the appointment of Jeffrey Yablon as director, business development, Matthew Stannard as senior manager of business development and Linda Brown as senior project manager.
"We're pleased to have such a talented and experienced group join ClinPro," said Rich Purcell, president of ClinPro, Inc. "Each new team member will play a pivotal role in ClinPro's mission of providing high-quality and cost-effective clinical trial management solutions."
As director, business development of ClinPro, Inc., Mr. Yablon brings a wealth of experience from the pharmaceutical, healthcare and clinical trials industries. In his new role, Mr. Yablon will identify new business opportunities, consult on clinical development strategy, and assist with corporate planning. In addition, he will prepare proposals, budget estimates and secure new contracts with companies in the drug development and medical device communities.
Most recently, Mr. Yablon was the chief operating officer for ICON Laboratories where he managed global operations for their central clinical trials laboratory and oversaw over 450 employees. In addition, he created new business opportunities that included pharmacogenomics and immunology businesses, and supervised the construction and development of ICON's new $25 million headquarters. Mr. Yablon holds an MBA from Fairleigh Dickinson University.
As senior manager of business development, Mr. Stannard is responsible for the development of ClinPro's new business opportunities, sales operations and strategic planning. Prior to his new position, Mr. Stannard spent six years in ClinPro's Clinical Operations Group where he managed several clinical trials, spending the latter portion of his years as Clinical Project Manager.
Mr. Stannard began his career as an analytical chemist where he received extensive hands-on experience in the development of several new drug entities. Mr. Stannard holds a B.A. in Molecular Biology from Lehigh University.
As senior project manager, Ms. Brown will oversee clinical development projects, and manage the day-to-day logistics of conducting clinical trials. She will be the primary point person for communications among our sponsors, investigators, and ClinPro staff, especially for studies in ClinPro's Center for Oncology Research Management (CORM).
Before joining ClinPro, Ms. Brown spent her 20-year career in a variety of roles in the pharmaceutical and biotechnology industries concentrating on project management, corporate communications, and clinical research. In addition, Ms. Brown has played a significant role in numerous product launches and marketing initiatives. Ms. Brown holds a B.A. in Biology from Gettysburg College.
ABOUT CLINPRO, INC.
ClinPro, Inc. is a growing, independent, full-service clinical research organization (CRO) with expertise in a variety of therapeutic areas. For more information on ClinPro's clinical trial services and expertise, contact ClinPro at (732) 868-0200. For media inquiries, contact Candace Vadnais at PFS Marketwyse (973) 812-8883, ext. 430 or visit ClinPro's Web site at www.clinproinc.com . ticlebody>
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
